Prescient Therapeutics LimitedASX: PTX

March 2018 Investor Presentation

· Issued by Prescient Therapeutics Limited

Filed with ASX · · 34 pages · English

Melbourne, Australia (19 March 2018): Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) provides a copy of the attached March 2018 Investor Presentation, ahead of final Phase 1b breast cancer results with PTX-200. For women with locally advanced ER+, HER2 negative breast cancer, typical expectations are a response rate of 25%. Prescient is currently undertaking t

Prescient Therapeutics Limited on 6ix

In the deck

Earlier from Prescient Therapeutics

Later from Prescient Therapeutics

All Prescient Therapeutics news releases